AV Therapeutics Successfully Completes GMP Synthesis of Its Lead Prostate Cancer Chemotherapeutic Drug, Capridine NEW YORK, Nov. 24, 2014 (GLOBE NEWSWIRE) -- AV Therapeutics, Inc. ("AV Therapeutics" or the "Company") (OTCQB:AVTH), a developer of cancer therapeutics and vaccines, is pleased to announce the...

Memorial Sloan-Kettering's Dr. Howard Scher Reaffirms Commitment to Lead Phase I Trials for AV Therapeutics' Prostate Cancer Drug NEW YORK, May 7, 2014 (GLOBE NEWSWIRE) -- AV Therapeutics, Inc. ("AV Therapeutics" or the "Company") (OTCQB:AVTH), a developer of cancer therapeutics and vaccines, announced Howard Scher, MD, Chief,...

AV Therapeutics Announces Collaboration With DavosPharma to Manufacture Chemotherapeutic Drug Capridine NEW YORK, Feb. 5, 2014 (GLOBE NEWSWIRE) -- AV Therapeutics, Inc., ("AV Therapeutics" or "the Company") (OTCQB:AVTH), a developer of cancer therapeutics and vaccines, today announced that it has...

AV Therapeutics Announces Information Available Through S&P's Corporation Records Program NEW YORK, Jan. 22, 2014 (GLOBE NEWSWIRE) -- AV Therapeutics, Inc. ("AV Therapeutics" or the "Company") (OTCQB:AVTH), a developer of cancer therapeutics and vaccines, announced that its company...

AV Therapeutics Begins Trading on the OTCQB Under the Symbol "AVTH" NEW YORK, Jan. 2, 2014 (GLOBE NEWSWIRE) -- AV Therapeutics, Inc. ("AV Therapeutics" or the "Company") (OTCQB:AVTH), a developer of cancer therapeutics and vaccines, announced that its common stock...